These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29977602)

  • 1. Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer.
    Ebhardt HA; Root A; Liu Y; Gauthier NP; Sander C; Aebersold R
    NPJ Syst Biol Appl; 2018; 4():26. PubMed ID: 29977602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based assessment and network analysis of targeting 14-3-3 proteins in prostate cancer.
    Root A; Beizaei A; Ebhardt HA
    Mol Cancer; 2018 Oct; 17(1):156. PubMed ID: 30382885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
    Edlind MP; Hsieh AC
    Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
    Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
    Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
    Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
    Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
    Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circular RNA cir-ITCH Is a Potential Therapeutic Target for the Treatment of Castration-Resistant Prostate Cancer.
    Li S; Yu C; Zhang Y; Liu J; Jia Y; Sun F; Zhang P; Li J; Guo L; Xiao H; Gao F; Deng X; Cai Z; Cai J
    Biomed Res Int; 2020; 2020():7586521. PubMed ID: 32904490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells.
    Chang PC; Wang TY; Chang YT; Chu CY; Lee CL; Hsu HW; Zhou TA; Wu Z; Kim RH; Desai SJ; Liu S; Kung HJ
    PLoS One; 2014; 9(2):e88556. PubMed ID: 24551118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
    Liu Z; Zhu G; Getzenberg RH; Veltri RW
    J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition.
    Ding G; Feng C; Jiang H; Ding Q; Zhang L; Na R; Xu H; Liu J
    PLoS One; 2013; 8(10):e77400. PubMed ID: 24130883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
    Liu L; Dong X
    PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.
    Mandel A; Larsson P; Sarwar M; Semenas J; Syed Khaja AS; Persson JL
    Mol Med; 2018 Jun; 24(1):34. PubMed ID: 30134822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
    Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
    Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
    Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications.
    Pisano C; Tucci M; Di Stefano RF; Turco F; Scagliotti GV; Di Maio M; Buttigliero C
    Crit Rev Oncol Hematol; 2021 Jan; 157():103185. PubMed ID: 33341506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
    Ma T; Chen H; Wang P; Yang N; Bao J
    Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.